Categories: News

2 Days to Go: Crypto Content Creator Campus Launches Kaito-Powered Mindshare Leaderboard to Celebrate the Voices Shaping Web3 Conversations

LISBON, Portugal, Nov. 12, 2025 /PRNewswire/ — The Crypto Content Creator Campus (CCCC) has partnered with Kaito, the AI-powered crypto intelligence platform, to launch the CCCC Mindshare Leaderboard — a first-of-its-kind ranking that measures real-time influence and engagement across the crypto content space.

- Advertisement -

Accessible here:  https://yaps.kaito.ai/cccc

- Advertisement -

Running from now until November 21, the Kaito Mindshare Leaderboard will reward the creators, KOLs, and communities driving meaningful conversations around #CCCCampus and #CCCCLisbon2025. With $5,000 in rewards and a chance to win a special prize, the leaderboard aims to amplify the voices shaping the future of crypto storytelling.

- Advertisement -

Rewarding Real Influence, Not Volume

- Advertisement -

The Kaito-powered system ranks participants based on the authenticity and impact of their content, rather than follower count or posting frequency. Engagement from credible and recognized voices boosts scores, allowing both established and emerging creators to gain visibility through meaningful contributions.

- Advertisement -

During the CCCC event, the leaderboard will continue updating in real time, with Mindshare Scores integrated into the final judging process — ensuring that both on-site performance and online influence are fairly represented.

- Advertisement -

“Kaito’s Mindshare analytics introduce a new way to quantify influence and celebrate authentic participation,” said a CCCC spokesperson. “We’re highlighting the creators who truly shape narratives across the Web3 space.”

- Advertisement -

Spotlighting Global Crypto Creators at CCCC Lisbon

- Advertisement -

The Lisbon event will feature leading voices from the global crypto community, including Waqar Zaka, Coin Bureau, Davinci Jeremie, MMCrypto, Carl Runefelt (The Moon), Ran Neuner, Tasso Lago, TradingLab, Fefe Demeny, Daviddtech, and European Kid, alongside a new generation of rising content creators.

- Advertisement -

Event Details:

- Advertisement -

About Crypto Content Creator Campus (CCCC)

- Advertisement -

CCCC is a team of industry experts and visionaries committed to shaping the future of content creation within the Web3 and crypto sphere. Driven by a shared passion for creating a high-value community, we’ve curated a campus that promises an experience unlike any other.  The CCCC 2025 will be held in Lisbon, Portugal, from November 14 to 16, 2025.

- Advertisement -

For more details about CCCC, please visit: https://www.cccc.buzz/
For inquiries, please contact: hello@cccc.buzz 

- Advertisement -


Instagram
  | X

- Advertisement -

Logo – https://mma.prnewswire.com/media/2820012/CCCC_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/2-days-to-go-crypto-content-creator-campus-launches-kaito-powered-mindshare-leaderboard-to-celebrate-the-voices-shaping-web3-conversations-302613264.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

5 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

5 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

5 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

5 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

5 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

5 hours ago